Wednesday, July 8, 2026

Patent intelligence · US

US 12156940

Manufacturing of bupivacaine multivesicular liposomes

granted A61KA61K31/445A61K47/14A61K47/24
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 57
Patent details — US 12156940
Jurisdiction
US
Status
granted
Grant date
Dec 3, 2024
Expiration
Nov 28, 2044
Claims
30
CPC classes
A61K, A61K31/445, A61K47/14, A61K47/24
View on Google Patents ↗

Quick answer

US 12156940 (Manufacturing of bupivacaine multivesicular liposomes) is held by Pacira Pharmaceuticals, Inc.. Status: granted. Granted Dec 3, 2024. Expires Nov 28, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
30
CPC classes
A61K, A61K31/445, A61K47/14, A61K47/24, A61K47/28, A61K9/10

More from Pacira Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12370142

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Expires Jul 24, 2045

    granted
  2. US 12364764

    Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same

    Pacira Therapeutics, Inc. · Expires Jul 17, 2045

    granted
  3. US 12318483

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Expires May 29, 2045

    granted
  4. US 12296047

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Expires May 8, 2045

    granted
  5. US 12285435

    Multivesicular liposome formulations of dexamethasone

    Pacira Pharmaceuticals, Inc. · Expires Apr 24, 2045

    granted
  6. US 12285419

    Bupivacaine multivesicular liposome formulations and uses thereof

    Pacira Pharmaceuticals, Inc. · Expires Apr 24, 2045

    granted
  7. US 12280149

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Expires Apr 17, 2045

    granted
  8. US 12251472

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Expires Mar 13, 2045

    granted

Frequently asked questions

What is US patent 12156940?

US 12156940 (Manufacturing of bupivacaine multivesicular liposomes) is held by Pacira Pharmaceuticals, Inc.. Status: granted. Granted Dec 3, 2024. Expires Nov 28, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12156940?

Pacira Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.

When does US 12156940 expire?

Our index shows an expiration date of Nov 28, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.